Search
Bafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThese compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase).
Quaternium-18
go.drugbank.com/drugs/DB11305ApprovedWithdrawnAcute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Eptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...
Atamparib
go.drugbank.com/drugs/DB19028InvestigationalAtamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).
Bifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
Daleuton
go.drugbank.com/drugs/DB00154InvestigationalNutraceuticalA 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Synonyms: 20:3, n-6,9,12 all-cis, C20:3, n-6,9,12 all-cisNecuparanib
go.drugbank.com/drugs/DB16251InvestigationalNecuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).